Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01063283 · ClinicalTrials.gov registry record · NA
Dose Escalation of Bevacizumab With Ambulatory Blood Pressure Monitoring in Patients With Advanced Non-squamous NSCLC
A NA study, sponsored by University of Chicago.
- Completed
- Registry status
- NA
- Development phase
- 20
- Enrollment target
NCT01063283 is a NA study that has completed, run by University of Chicago. The registered enrollment target is 20 participants.
The verdict
NCT01063283, a NA study, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to see if higher dose of bevacizumab can be taken safely by some patients and if changes in the dose of bevacizumab have any effect on blood pressure.
Interventions
- DRUG Carboplatin
- DRUG Pemetrexed
- DRUG Bevacizumab 15 mg/kg
- DRUG Bevacizumab 7.5 mg/kg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2010-03 |
| Est. Completion | 2016-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01063283
The ClinicalTrials.gov registry entry for NCT01063283 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Carboplatin is the first listed.
NCT01063283 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01063283 about?
NCT01063283 is a clinical study titled "Dose Escalation of Bevacizumab With Ambulatory Blood Pressure Monitoring in Patients With Advanced Non-squamous NSCLC". The purpose of this study is to see if higher dose of bevacizumab can be taken safely by some patients and if changes in the dose of bevacizumab have any effect on blood pressure.
What is the current status of trial NCT01063283?
This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2010-03. Estimated completion is 2016-06.
What interventions are being tested in trial NCT01063283?
The interventions under investigation include: Carboplatin (DRUG), Pemetrexed (DRUG), Bevacizumab 15 mg/kg (DRUG), Bevacizumab 7.5 mg/kg (DRUG).
Who is sponsoring clinical trial NCT01063283?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.